{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:35:09Z","timestamp":1791668109017,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jcf.2025.03.015","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T15:17:59Z","timestamp":1748272679000},"page":"691-697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0025-2422","authenticated-orcid":false,"given":"Natalie E.","family":"West","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-7277","authenticated-orcid":false,"given":"Michael W.","family":"Konstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Flume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-8164","authenticated-orcid":false,"given":"Donald R.","family":"VanDevanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1221-3746","authenticated-orcid":false,"given":"Amalia","family":"Magaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6392-1996","authenticated-orcid":false,"given":"Henryk","family":"Mazurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5356-9415","authenticated-orcid":false,"given":"Elena L.","family":"Amelina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Laki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Chiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivagurunathan","family":"Sutharsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Columbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5238-7264","authenticated-orcid":false,"given":"Henry L.","family":"Dorkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6471-549X","authenticated-orcid":false,"given":"Damian G.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2031-2063","authenticated-orcid":false,"given":"Amparo","family":"Sole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Hjelte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Tullis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Dgetluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Constantine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4495-4693","authenticated-orcid":false,"given":"James F.","family":"Chmiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2025.03.015_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"10212","key":"10.1016\/j.jcf.2025.03.015_bib0002","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2025.03.015_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10059","key":"10.1016\/j.jcf.2025.03.015_bib0004","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jcf.2025.03.015_bib0005","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.015_bib0006","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.jcf.2025.03.015_bib0007","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1164\/rccm.201608-1678LE","article-title":"Patients with cystic fibrosis and a G551D or homozygous F508del mutation: similar lung function decline","volume":"195","author":"Sawicki","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 3","key":"10.1016\/j.jcf.2025.03.015_bib0008","first-page":"S46","article-title":"Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators","volume":"54","author":"Perrem","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.jcf.2025.03.015_bib0009","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","article-title":"Inflammation in cystic fibrosis lung disease: pathogenesis and therapy","volume":"14","author":"Cantin","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.03.015_bib0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/ni1056","article-title":"Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway","volume":"5","author":"Karp","year":"2004","journal-title":"Nat Immunol"},{"issue":"11","key":"10.1016\/j.jcf.2025.03.015_bib0011","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/17476348.2019.1666715","article-title":"Targeting airway inflammation in cystic fibrosis","volume":"13","author":"McElvaney","year":"2019","journal-title":"Expert Rev Respir Med"},{"issue":"7","key":"10.1016\/j.jcf.2025.03.015_bib0012","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"S3","key":"10.1016\/j.jcf.2025.03.015_bib0013","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ppul.24129","article-title":"Inflammation in cystic fibrosis: an update","volume":"53","author":"Roesch","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2025.03.015_bib0014","doi-asserted-by":"crossref","first-page":"E833","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system","volume":"19","author":"Zou","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.jcf.2025.03.015_bib0015","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/j.bmc.2014.04.062","article-title":"Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity","volume":"22","author":"Tepper","year":"2014","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"10.1016\/j.jcf.2025.03.015_bib0016","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","article-title":"Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis","volume":"71","author":"Gonzalez","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jcf.2025.03.015_bib0017","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cpt.980","article-title":"Potent anti-inflammatory and pro-resolving effects of anabasum in a human model of self-resolving acute inflammation","volume":"104","author":"Motwani","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jcf.2025.03.015_bib0018","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-2952(02)01604-0","article-title":"Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid","volume":"65","author":"Zurier","year":"2003","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.015_bib0019","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/molpharm.120.000083","article-title":"Molecular mechanisms for the inflammation-resolving actions of lenabasum","volume":"99","author":"Burstein","year":"2021","journal-title":"Mol Pharmacol"},{"issue":"7503","key":"10.1016\/j.jcf.2025.03.015_bib0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jcf.2025.03.015_bib0021","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jcf.2020.03.015","article-title":"Anti-inflammatory effects of lenabasum, a cannabinoid receptor type 2 agonist, on macrophages from cystic fibrosis","volume":"19","author":"Tarique","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.03.015_bib0022","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcf.2020.09.008","article-title":"Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis","volume":"20","author":"Chmiel","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.03.015_bib0023","first-page":"61","article-title":"Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis","volume":"40","author":"Waters","year":"2012","journal-title":"EurRespirJ"},{"issue":"4","key":"10.1016\/j.jcf.2025.03.015_bib0024","first-page":"345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"AmJEpidemiol"},{"issue":"11","key":"10.1016\/j.jcf.2025.03.015_bib0025","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment","volume":"204","author":"Goss","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.jcf.2025.03.015_bib0026","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"NEnglJMed"},{"key":"10.1016\/j.jcf.2025.03.015_bib0027","first-page":"A251","article-title":"Validation of a novel patient-reported respiratory symptoms instrument in cystic fibrosis: CFRSD-CRISS","volume":"36","author":"Goss","year":"2013","journal-title":"Pediatr Pulmonol;"},{"key":"10.1016\/j.jcf.2025.03.015_bib0028","series-title":"2018 Annual Data Report","article-title":"Cystic fibrosis foundation patient registry","year":"2019"},{"issue":"1","key":"10.1016\/j.jcf.2025.03.015_bib0029","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcf.2020.07.008","article-title":"Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials","volume":"20","author":"VanDevanter","year":"2021","journal-title":"J. Cystic Fibrosis"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325001110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325001110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:14:51Z","timestamp":1778822091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325001110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1569199325001110"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.03.015","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}